{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:29:58Z","timestamp":1793640598071,"version":"4.5.1"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Cedars-Sinai Medical Center","id":[{"id":"https:\/\/ror.org\/02pammg90","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40257-026-01066-7","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:23:07Z","timestamp":1789975387000},"page":"1225-1238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rosacea in Patients with Skin of Color: Diagnosis and Management"],"prefix":"10.1007","volume":"27","author":[{"given":"Devina","family":"Lohani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8832-0735","authenticated-orcid":false,"given":"Justin W.","family":"Marson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary E.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"1","key":"1066_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/jidsymp.2011.8","volume":"15","author":"AA Aubdool","year":"2011","unstructured":"Aubdool AA, Brain SD. Neurovascular aspects of skin neurogenic inflammation. J Investig Dermatol Symp Proc. 2011;15(1):33\u20139. https:\/\/doi.org\/10.1038\/jidsymp.2011.8.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"1","key":"1066_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/jidsymp.2011.6","volume":"15","author":"VD Schwab","year":"2011","unstructured":"Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15(1):53\u201362. https:\/\/doi.org\/10.1038\/jidsymp.2011.6.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"2","key":"1066_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1468-3083.2010.03751.x","volume":"25","author":"BE Elewski","year":"2011","unstructured":"Elewski BE, Draelos Z, Dr\u00e9no B, Jansen T, Layton A, Picardo M. Rosacea - global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol. 2011;25(2):188\u2013200. https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03751.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1066_CR4","doi-asserted-by":"publisher","DOI":"10.1080\/19381980.2017.1361574","volume":"9","author":"BM Rainer","year":"2017","unstructured":"Rainer BM, Kang S, Chien AL. Rosacea: epidemiology, pathogenesis, and treatment. Dermatoendocrinology. 2017;9(1):e1361574. https:\/\/doi.org\/10.1080\/19381980.2017.1361574.","journal-title":"Dermatoendocrinology"},{"issue":"4","key":"1066_CR5","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1067\/mjd.2002.120625","volume":"46","author":"J Wilkin","year":"2002","unstructured":"Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46(4):584\u20137. https:\/\/doi.org\/10.1067\/mjd.2002.120625.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1066_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/bjd.16481","volume":"179","author":"L Gether","year":"2018","unstructured":"Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018;179(2):282\u20139. https:\/\/doi.org\/10.1111\/bjd.16481.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1066_CR7","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.jaad.2018.08.049","volume":"80","author":"AF Alexis","year":"2019","unstructured":"Alexis AF, Callender VD, Baldwin HE, Desai SR, Rendon MI, Taylor SC. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: review and clinical practice experience. J Am Acad Dermatol. 2019;80(6):1722-1729.e7. https:\/\/doi.org\/10.1016\/j.jaad.2018.08.049.","journal-title":"J Am Acad Dermatol"},{"key":"1066_CR8","doi-asserted-by":"crossref","unstructured":"Al-Dabagh A, Davis SA, McMichael AJ, Feldman SR. Rosacea in skin of color: not a rare diagnosis. Dermatol Online J. 2014;20(10):13030\/qt1mv9r0ss. PMID: 25526008","DOI":"10.5070\/D32010024262"},{"issue":"5","key":"1066_CR9","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1468-3083.2009.03472.x","volume":"24","author":"K Abram","year":"2010","unstructured":"Abram K, Silm H, Maaroos HI, Oona M. Risk factors associated with rosacea. J Eur Acad Dermatol Venereol. 2010;24(5):565\u201371. https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03472.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1066_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.5021\/ad.2009.21.3.243","volume":"21","author":"YI Bae","year":"2009","unstructured":"Bae YI, Yun SJ, Lee JB, Kim SJ, Won YH, Lee SC. Clinical evaluation of 168 Korean patients with rosacea: the sun exposure correlates with the erythematotelangiectatic subtype. Ann Dermatol. 2009;21(3):243\u20139. https:\/\/doi.org\/10.5021\/ad.2009.21.3.243.","journal-title":"Ann Dermatol"},{"issue":"5","key":"1066_CR11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/ijd.13491","volume":"56","author":"LJ Rueda","year":"2017","unstructured":"Rueda LJ, Motta A, Pab\u00f3n JG, et al. Epidemiology of rosacea in Colombia. Int J Dermatol. 2017;56(5):510\u20133. https:\/\/doi.org\/10.1111\/ijd.13491.","journal-title":"Int J Dermatol"},{"issue":"6","key":"1066_CR12","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/ced.13177","volume":"42","author":"NC Dlova","year":"2017","unstructured":"Dlova NC, Mosam A. Rosacea in Black South Africans with skin phototypes V and VI. Clin Exp Dermatol. 2017;42(6):670\u20133. https:\/\/doi.org\/10.1111\/ced.13177.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1066_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/jamadermatol.2022.0526","volume":"158","author":"YA Barakji","year":"2022","unstructured":"Barakji YA, R\u00f8nnstad ATM, Christensen MO, et al. Assessment of frequency of rosacea subtypes in patients with rosacea: a systematic review and meta-analysis. JAMA Dermatol. 2022;158(6):617\u201325. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0526.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"1066_CR14","first-page":"608","volume":"18","author":"A Cices","year":"2019","unstructured":"Cices A, Alexis AF. Patient-focused solutions in rosacea management: treatment challenges in special patient groups. J Drugs Dermatol. 2019;18(7):608\u201312.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"1066_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bjd.15122","volume":"176","author":"J Tan","year":"2017","unstructured":"Tan J, Almeida LMC, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176(2):431\u20138. https:\/\/doi.org\/10.1111\/bjd.15122.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1066_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaad.2017.08.037","volume":"78","author":"RL Gallo","year":"2017","unstructured":"Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2017;78(1):148\u201355. https:\/\/doi.org\/10.1016\/j.jaad.2017.08.037.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1066_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/exd.13514","volume":"27","author":"BP Kaufman","year":"2018","unstructured":"Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups-variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27(4):340\u201357. https:\/\/doi.org\/10.1111\/exd.13514.","journal-title":"Exp Dermatol"},{"issue":"6","key":"1066_CR18","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.jaad.2009.08.020","volume":"62","author":"SP Kini","year":"2010","unstructured":"Kini SP, Nicholson K, DeLong LK, et al. A pilot study in discrepancies in quality of life among three cutaneous types of rosacea. J Am Acad Dermatol. 2010;62(6):1069\u201371. https:\/\/doi.org\/10.1016\/j.jaad.2009.08.020.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1066_CR19","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/cpp.763","volume":"19","author":"D Su","year":"2012","unstructured":"Su D, Drummond PD. Blushing propensity and psychological distress in people with rosacea. Clin Psychol Psychother. 2012;19(6):488\u201395. https:\/\/doi.org\/10.1002\/cpp.763.","journal-title":"Clin Psychol Psychother"},{"issue":"2","key":"1066_CR20","first-page":"120","volume":"8","author":"BE Elewski","year":"2009","unstructured":"Elewski BE. Results of a national rosacea patient survey: common issues that concern rosacea sufferers. J Drugs Dermatol. 2009;8(2):120\u20133.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"1066_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.1365-2133.2010.09894.x","volume":"163","author":"B Aksoy","year":"2010","unstructured":"Aksoy B, Altaykan-Hapa A, Egemen D, Karag\u00f6z F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol. 2010;163(4):719\u201325. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09894.x.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1066_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jaad.2021.12.062","volume":"87","author":"K Shao","year":"2022","unstructured":"Shao K, Hooper J, Feng H. Racial and ethnic health disparities in dermatology in the United States. Part 2: disease-specific epidemiology, characteristics, management, and outcomes. J Am Acad Dermatol. 2022;87(4):733\u201344. https:\/\/doi.org\/10.1016\/j.jaad.2021.12.062.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1066_CR23","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/jocd.14178","volume":"21","author":"Z Deng","year":"2022","unstructured":"Deng Z, Yan S, Li J, et al. The association between rosacea and the condition of low tolerance to skincare of the facial skin: a case-control study in China. J Cosmet Dermatol. 2022;21(3):1171\u20137. https:\/\/doi.org\/10.1111\/jocd.14178.","journal-title":"J Cosmet Dermatol"},{"issue":"11","key":"1066_CR24","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1001\/jamadermatol.2015.2230","volume":"151","author":"N Aldrich","year":"2015","unstructured":"Aldrich N, Gerstenblith M, Fu P, et al. Genetic vs environmental factors that correlate with rosacea: a cohort-based survey of twins. JAMA Dermatol. 2015;151(11):1213\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2015.2230.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1066_CR25","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/jid.2015.53","volume":"135","author":"ALS Chang","year":"2015","unstructured":"Chang ALS, Raber I, Xu J, et al. Assessment of the genetic basis of rosacea by genome-wide association study. J Investig Dermatol. 2015;135(6):1548\u201355. https:\/\/doi.org\/10.1038\/jid.2015.53.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"1066_CR26","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1080\/07853890.2022.2077427","volume":"54","author":"W Xiao","year":"2022","unstructured":"Xiao W, Li J, Huang X, et al. Mediation roles of neutrophils and high-density lipoprotein (HDL) on the relationship between HLA-DQB1 and rosacea. Ann Med. 2022;54(1):1530\u20137. https:\/\/doi.org\/10.1080\/07853890.2022.2077427.","journal-title":"Ann Med"},{"issue":"1","key":"1066_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39761-2","volume":"14","author":"Z Deng","year":"2023","unstructured":"Deng Z, Chen M, Zhao Z, et al. Whole genome sequencing identifies genetic variants associated with neurogenic inflammation in rosacea. Nat Commun. 2023;14(1):3958. https:\/\/doi.org\/10.1038\/s41467-023-39761-2.","journal-title":"Nat Commun"},{"issue":"6","key":"1066_CR28","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1111\/ijd.14757","volume":"59","author":"JW Marson","year":"2020","unstructured":"Marson JW, Baldwin HE. Rosacea: a wholistic review and update from pathogenesis to diagnosis and therapy. Int J Dermatol. 2020;59(6):e175\u201382. https:\/\/doi.org\/10.1111\/ijd.14757.","journal-title":"Int J Dermatol"},{"issue":"2","key":"1066_CR29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/ceo.13900","volume":"49","author":"S Tavassoli","year":"2021","unstructured":"Tavassoli S, Wong N, Chan E. Ocular manifestations of rosacea: a clinical review. Clin Exp Ophthalmol. 2021;49(2):104\u201317. https:\/\/doi.org\/10.1111\/ceo.13900.","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"1066_CR30","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/0002-9394(86)90644-6","volume":"101","author":"DJ Browning","year":"1986","unstructured":"Browning DJ, Rosenwasser G, Lugo M. Ocular rosacea in blacks. Am J Ophthalmol. 1986;101(4):441\u20134. https:\/\/doi.org\/10.1016\/0002-9394(86)90644-6.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"1066_CR31","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/opx.0000000000001879","volume":"99","author":"O Bass","year":"2022","unstructured":"Bass O, Crane D. Case series: underdiagnosis of ocular and oculocutaneous rosacea in an African American pediatric population. Optom Vis Sci. 2022;99(6):521\u20137. https:\/\/doi.org\/10.1097\/opx.0000000000001879.","journal-title":"Optom Vis Sci"},{"issue":"5","key":"1066_CR32","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2310\/7750.2008.08051","volume":"13","author":"N Ezra","year":"2009","unstructured":"Ezra N, Greco JF, Haley JC, Chiu MW. Gnatophyma and otophyma. J Cutan Med Surg. 2009;13(5):266\u201372. https:\/\/doi.org\/10.2310\/7750.2008.08051.","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"1066_CR33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/ICO.0000000000003785","volume":"44","author":"K Mohamed-Noriega","year":"2025","unstructured":"Mohamed-Noriega K, Loya-Garcia D, Vera-Duarte GR, Morales-Wong F, Ortiz-Morales G, Navas A, et al. Ocular rosacea: an updated review. Cornea. 2025;44(4):525\u201337. https:\/\/doi.org\/10.1097\/ICO.0000000000003785. (Epub 2025 Jan 14; PMID: 39808113; PMCID: PMC11872267).","journal-title":"Cornea"},{"issue":"6","key":"1066_CR34","doi-asserted-by":"publisher","first-page":"574","DOI":"10.36849\/JDD.6838","volume":"21","author":"A Alexis","year":"2022","unstructured":"Alexis A, Woolery-Lloyd H, Andriessen A, Desai S, Han G, Rodriguez D. Improving rosacea outcomes in skin of color patients: a review on the nuances in the treatment and the use of cleansers and moisturizers. J Drugs Dermatol. 2022;21(6):574\u201380. https:\/\/doi.org\/10.36849\/JDD.6838.","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"1066_CR35","doi-asserted-by":"publisher","first-page":"Sf3502913","DOI":"10.36849\/jdd.m0922","volume":"21","author":"J Marson","year":"2022","unstructured":"Marson J, Baldwin H. Supplement article: dysbiosis, (barrier) dysfunction, and dermatoses: a chicken-and-egg dilemma. J Drugs Dermatol. 2022;21(9):Sf3502913\u20134. https:\/\/doi.org\/10.36849\/jdd.m0922.","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"1066_CR36","doi-asserted-by":"publisher","first-page":"Sf3502915","DOI":"10.36849\/JDD.m0922","volume":"21","author":"J Marson","year":"2022","unstructured":"Marson J, Bhatia N, Graber E, et al. Supplement article: the role of epidermal barrier dysfunction and cutaneous microbiome dysbiosis in the pathogenesis and management of acne vulgaris and rosacea. J Drugs Dermatol. 2022;21(9):Sf3502915\u201335029114. https:\/\/doi.org\/10.36849\/JDD.m0922.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1066_CR37","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.jaad.2020.04.079","volume":"84","author":"AB Lyons","year":"2021","unstructured":"Lyons AB, Trullas C, Kohli I, Hamzavi IH, Lim HW. Photoprotection beyond ultraviolet radiation: a review of tinted sunscreens. J Am Acad Dermatol. 2021;84(5):1393\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.079.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1066_CR38","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/s0733-8635(05)70213-8","volume":"18","author":"ZD Draelos","year":"2000","unstructured":"Draelos ZD. Colored facial cosmetics. Dermatol Clin. 2000;18(4):621\u201331. https:\/\/doi.org\/10.1016\/s0733-8635(05)70213-8.","journal-title":"Dermatol Clin"},{"issue":"12","key":"1066_CR39","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1111\/jdv.13305","volume":"29","author":"AM Layton","year":"2015","unstructured":"Layton AM, Schaller M, Homey B, et al. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. J Eur Acad Dermatol Venereol. 2015;29(12):2405\u201310. https:\/\/doi.org\/10.1111\/jdv.13305.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1066_CR40","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1365-2133.2011.10716.x","volume":"166","author":"J Fowler","year":"2012","unstructured":"Fowler J, Jarratt M, Moore A, et al. Once-daily topical brimonidine tartrate gel 0\u00b75% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166(3):633\u201341. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10716.x.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1066_CR41","first-page":"650","volume":"12","author":"J Fowler Jr","year":"2013","unstructured":"Fowler J Jr, Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1066_CR42","first-page":"56","volume":"13","author":"A Moore","year":"2014","unstructured":"Moore A, Kempers S, Murakawa G, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014;13(1):56\u201361.","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"1066_CR43","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1001\/jamadermatol.2015.1252","volume":"151","author":"R Gillihan","year":"2015","unstructured":"Gillihan R, Nguyen T, Fischer R, Rajpara A, Aires D. Erythema in skin adjacent to area of long-term brimonidine treatment for rosacea: a novel adverse reaction. JAMA Dermatol. 2015;151(10):1136\u20137. https:\/\/doi.org\/10.1001\/jamadermatol.2015.1252.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1066_CR44","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/j.jaad.2013.10.054","volume":"70","author":"ET Routt","year":"2014","unstructured":"Routt ET, Levitt JO. Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%. J Am Acad Dermatol. 2014;70(2):e37\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2013.10.054.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1066_CR45","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1016\/j.jaad.2014.01.853","volume":"70","author":"D Ilkovitch","year":"2014","unstructured":"Ilkovitch D, Pomerantz RG. Brimonidine effective but may lead to significant rebound erythema. J Am Acad Dermatol. 2014;70(5):e109\u201310. https:\/\/doi.org\/10.1016\/j.jaad.2014.01.853.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1066_CR46","first-page":"97","volume":"17","author":"LH Kircik","year":"2018","unstructured":"Kircik LH, DuBois J, Draelos ZD, et al. Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the first REVEAL trial. J Drugs Dermatol. 2018;17(1):97\u2013105.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"1066_CR47","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jaad.2018.01.027","volume":"78","author":"ZD Draelos","year":"2018","unstructured":"Draelos ZD, Gold MH, Weiss RA, et al. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 52-week open label REVEAL trial. J Am Acad Dermatol. 2018;78(6):1156\u201363. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.027.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1066_CR48","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/s0733-8635(03)00086-x","volume":"21","author":"EF Battle Jr.","year":"2003","unstructured":"Battle EF Jr., Hobbs LM. Laser therapy on darker ethnic skin. Dermatol Clin. 2003;21(4):713\u201323. https:\/\/doi.org\/10.1016\/s0733-8635(03)00086-x.","journal-title":"Dermatol Clin"},{"issue":"5","key":"1066_CR49","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/archderm.1987.01660290077020","volume":"123","author":"PA Bleicher","year":"1987","unstructured":"Bleicher PA, Charles JH, Sober AJ. Topical metronidazole therapy for rosacea. Arch Dermatol. 1987;123(5):609\u201314.","journal-title":"Arch Dermatol"},{"issue":"1","key":"1066_CR50","first-page":"44","volume":"61","author":"DL Breneman","year":"1998","unstructured":"Breneman DL, Stewart D, Hevia O, Hino PD, Drake LA. A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea. Cutis. 1998;61(1):44\u20137.","journal-title":"Cutis"},{"issue":"6","key":"1066_CR51","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1001\/archderm.134.6.679","volume":"134","author":"MV Dahl","year":"1998","unstructured":"Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134(6):679\u201383. https:\/\/doi.org\/10.1001\/archderm.134.6.679.","journal-title":"Arch Dermatol"},{"issue":"11","key":"1066_CR52","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1001\/archderm.139.11.1444","volume":"139","author":"BE Elewski","year":"2003","unstructured":"Elewski BE, Fleischer AB, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139(11):1444\u201350. https:\/\/doi.org\/10.1001\/archderm.139.11.1444.","journal-title":"Arch Dermatol"},{"issue":"1","key":"1066_CR53","first-page":"73","volume":"79","author":"JE Wolf Jr","year":"2007","unstructured":"Wolf JE Jr, Del Rosso JQ. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis. 2007;79(1):73\u201380.","journal-title":"Cutis"},{"issue":"4","key":"1066_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003262.pub5","volume":"2015","author":"EJ van Zuuren","year":"2015","unstructured":"van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for rosacea. Cochrane Database Syst Rev. 2015;2015(4):CD003262. https:\/\/doi.org\/10.1002\/14651858.CD003262.pub5.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1066_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/bjd.17590","volume":"181","author":"EJ van Zuuren","year":"2019","unstructured":"van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019;181(1):65\u201379. https:\/\/doi.org\/10.1111\/bjd.17590.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1066_CR56","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1080\/000155599750009906","volume":"79","author":"R Bjerke","year":"1999","unstructured":"Bjerke R, Fyrand O, Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea. Acta Derm Venereol. 1999;79(6):456\u20139. https:\/\/doi.org\/10.1080\/000155599750009906.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1066_CR57","first-page":"317","volume":"79","author":"LE Col\u00f3n","year":"2007","unstructured":"Col\u00f3n LE, Johnson LA, Gottschalk RW. Cumulative irritation potential among metronidazole gel 1%, metronidazole gel 0.75%, and azelaic acid gel 15%. Cutis. 2007;79(4):317\u201321.","journal-title":"Cutis"},{"issue":"6","key":"1066_CR58","first-page":"541","volume":"7","author":"DM Thiboutot","year":"2008","unstructured":"Thiboutot DM, Fleischer AB Jr, Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol. 2008;7(6):541\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"1066_CR59","first-page":"727","volume":"4","author":"K Ziel","year":"2005","unstructured":"Ziel K, Yelverton CB, Balkrishnan R, Feldman SR. Cumulative irritation potential of metronidazole gel compared to azelaic acid gel after repeated applications to healthy skin. J Drugs Dermatol. 2005;4(6):727\u201331.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"1066_CR60","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13093","volume":"32","author":"I Trave","year":"2019","unstructured":"Trave I, Merlo G, Cozzani E, Parodi A. Real-life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites. Dermatol Ther. 2019;32(6):e13093. https:\/\/doi.org\/10.1111\/dth.13093.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1066_CR61","first-page":"316","volume":"13","author":"L Stein","year":"2014","unstructured":"Stein L, Kircik L, Fowler J, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13(3):316\u201323.","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"1066_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15517","volume":"35","author":"HP Huang","year":"2022","unstructured":"Huang HP, Hsu CK, Lee JY. Topical ivermectin-induced transient flare of rosacea as a host reaction to killed Demodex mites preventable by short-term use of topical corticosteroid. Dermatol Ther. 2022;35(7):e15517. https:\/\/doi.org\/10.1111\/dth.15517.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1066_CR63","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/bjd.13408","volume":"172","author":"A Taieb","year":"2015","unstructured":"Taieb A, Ortonne JP, Ruzicka T, et al. Superiority of ivermectin 1% cream over metronidazole 0\u00b775% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172(4):1103\u201310. https:\/\/doi.org\/10.1111\/bjd.13408.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1066_CR64","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/jdv.13537","volume":"30","author":"A Taieb","year":"2016","unstructured":"Taieb A, Khemis A, Ruzicka T, et al. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. J Eur Acad Dermatol Venereol. 2016;30(5):829\u201336. https:\/\/doi.org\/10.1111\/jdv.13537.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1066_CR65","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.jaad.2020.01.043","volume":"82","author":"LS Gold","year":"2020","unstructured":"Gold LS, Del Rosso JQ, Kircik L, et al. Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: results of 2 phase 3, randomized, clinical trials. J Am Acad Dermatol. 2020;82(5):1166\u201373. https:\/\/doi.org\/10.1016\/j.jaad.2020.01.043.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1066_CR66","first-page":"44","volume":"13","author":"L Stein Gold","year":"2020","unstructured":"Stein Gold L, Del Rosso JQ, Kircik L, et al. Open-label extension study evaluating long-term safety and efficacy of FMX103 1.5% minocycline topical foam for the treatment of moderate-to-severe papulopustular rosacea. J Clin Aesthet Dermatol. 2020;13(11):44\u20139.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"4","key":"1066_CR67","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40257-021-00595-7","volume":"22","author":"EJ van Zuuren","year":"2021","unstructured":"van Zuuren EJ, Arents BWM, van der Linden MMD, Vermeulen S, Fedorowicz Z, Tan J. Rosacea: new concepts in classification and treatment. Am J Clin Dermatol. 2021;22(4):457\u201365. https:\/\/doi.org\/10.1007\/s40257-021-00595-7.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1066_CR68","first-page":"36","volume":"15","author":"LJ Green","year":"2022","unstructured":"Green LJ, Lain E, Prunty T, Rhoades R. Enhancing topical pharmacotherapy for acne and rosacea: vehicle choices and outcomes. J Clin Aesthet Dermatol. 2022;15(5):36\u201340.","journal-title":"J Clin Aesthet Dermatol."},{"key":"1066_CR69","unstructured":"Sol-Gel Technologies L. A Study of S5G4T-1 in the Treatment of Papular-pustular Rosacea. ClinicalTrialsgov. 2023;Identifier NCT03564119 (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03564119)."},{"key":"1066_CR70","unstructured":"Sol-gel technologies and galderma announce FDA approval of epsolay. April 25, 2022, Accessed 26 Nov 2022."},{"issue":"6","key":"1066_CR71","first-page":"685","volume":"13","author":"JJ Leyden","year":"2014","unstructured":"Leyden JJ. Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. J Drugs Dermatol. 2014;13(6):685\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1066_CR72","doi-asserted-by":"publisher","first-page":"s25","DOI":"10.25251\/skin.5.supp.25","volume":"5","author":"N Bhatia","year":"2021","unstructured":"Bhatia N, Werschler W, Baldwin H, et al. Long-term efficacy and safety of benzoyl peroxide cream, 5%, prepared with microencapsulation in papulopustular rosacea: results from an extension of two phase 3, vehicle-controlled trials. SKIN The Journal of Cutaneous Medicine. 2021;5(1):s25. https:\/\/doi.org\/10.25251\/skin.5.supp.25.","journal-title":"SKIN The Journal of Cutaneous Medicine."},{"issue":"5","key":"1066_CR73","first-page":"495","volume":"6","author":"JF Conde","year":"2007","unstructured":"Conde JF, Yelverton CB, Balkrishnan R, Fleischer AB Jr, Feldman SR. Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol. 2007;6(5):495\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"1066_CR74","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/j.1468-3083.2009.03167.x","volume":"23","author":"HC Korting","year":"2009","unstructured":"Korting HC, Sch\u00f6llmann C. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol. 2009;23(8):876\u201382. https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03167.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1066_CR75","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.phrs.2011.05.005","volume":"64","author":"MM Castro","year":"2011","unstructured":"Castro MM, Kandasamy AD, Youssef N, Schulz R. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. Pharmacol Res. 2011;64(6):551\u201360. https:\/\/doi.org\/10.1016\/j.phrs.2011.05.005.","journal-title":"Pharmacol Res"},{"issue":"1","key":"1066_CR76","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/ddg.14247","volume":"19","author":"H Husein-ElAhmed","year":"2021","unstructured":"Husein-ElAhmed H, Steinhoff M. Evaluation of the efficacy of subantimicrobial dose doxycycline in rosacea: a systematic review of clinical trials and meta-analysis. J Dtsch Dermatol Ges. 2021;19(1):7\u201317. https:\/\/doi.org\/10.1111\/ddg.14247.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"7","key":"1066_CR77","first-page":"664","volume":"8","author":"JQ Del Rosso","year":"2009","unstructured":"Del Rosso JQ. Anti-inflamatory dose doxycycline in the treatment of rosacea. J Drugs Dermatol. 2009;8(7):664\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1066_CR78","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","volume":"56","author":"JQ Del Rosso","year":"2007","unstructured":"Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791\u2013802. https:\/\/doi.org\/10.1016\/j.jaad.2006.11.021.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1066_CR79","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jaad.2005.04.069","volume":"53","author":"J Sanchez","year":"2005","unstructured":"Sanchez J, Somolinos AL, Almod\u00f3var PI, Webster G, Bradshaw M, Powala C. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol. 2005;53(5):791\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2005.04.069.","journal-title":"J Am Acad Dermatol"},{"issue":"5 Suppl","key":"1066_CR80","first-page":"7","volume":"86","author":"GF Webster","year":"2010","unstructured":"Webster GF. An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads). Cutis. 2010;86(5 Suppl):7\u201315.","journal-title":"Cutis"},{"issue":"10","key":"1066_CR81","first-page":"1219","volume":"11","author":"AF Alexis","year":"2012","unstructured":"Alexis AF, Webster G, Preston NJ, Caveney SW, Gottschalk RW. Effectiveness and safety of once-daily doxycycline capsules as monotherapy in patients with rosacea: an analysis by Fitzpatrick skin type. J Drugs Dermatol. 2012;11(10):1219\u201322.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"1066_CR82","first-page":"641","volume":"6","author":"JF Fowler Jr","year":"2007","unstructured":"Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6(6):641\u20135.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"1066_CR83","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jaad.2019.05.063","volume":"82","author":"M Schaller","year":"2020","unstructured":"Schaller M, Kem\u00e9ny L, Havlickova B, et al. A randomized phase 3b\/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol. 2020;82(2):336\u201343. https:\/\/doi.org\/10.1016\/j.jaad.2019.05.063.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1066_CR84","first-page":"16","volume":"14","author":"A Tsianakas","year":"2021","unstructured":"Tsianakas A, Pieber T, Baldwin H, et al. Minocycline extended-release comparison with doxycycline for the treatment of rosacea: a randomized, head-to-head, clinical trial. J Clin Aesthet Dermatol. 2021;14(12):16\u201323.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"3","key":"1066_CR85","doi-asserted-by":"publisher","first-page":"AB52","DOI":"10.1016\/j.jaad.2024.07.214","volume":"91","author":"S Sidgiddi","year":"2024","unstructured":"Sidgiddi S, Bhatia N, Sidgiddi S. 53889 Impact of DFD-29, a low-dose oral minocycline, on skin, gastrointestinal tract, and vaginal microflora in healthy adults: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024;91(3):AB52. https:\/\/doi.org\/10.1016\/j.jaad.2024.07.214.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1066_CR86","doi-asserted-by":"publisher","first-page":"426","DOI":"10.36849\/jdd.2021.5923","volume":"20","author":"JQ Rosso","year":"2021","unstructured":"Rosso JQ, Draelos ZD, Effron C, Kircik LH. Oral sarecycline for treatment of papulopustular rosacea: results of a pilot study of effectiveness and safety. J Drugs Dermatol. 2021;20(4):426\u201331. https:\/\/doi.org\/10.36849\/jdd.2021.5923.","journal-title":"J Drugs Dermatol"},{"key":"1066_CR87","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2147\/ccid.s190473","volume":"13","author":"AY Moore","year":"2020","unstructured":"Moore AY, Del Rosso J, Johnson JL, Grada A. Sarecycline: a review of preclinical and clinical evidence. Clin Cosmet Investig Dermatol. 2020;13:553\u201360. https:\/\/doi.org\/10.2147\/ccid.s190473.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1066_CR88","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01297-18","author":"G Zhanel","year":"2019","unstructured":"Zhanel G, Critchley I, Lin LY, Alvandi N. Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/aac.01297-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1066_CR89","first-page":"177","volume":"122","author":"J Gajardo","year":"1994","unstructured":"Gajardo J. Severe rosacea treated with oral isotretinoin. Rev Med Chil. 1994;122(2):177\u20139 (Ros\u00e1cea severa tratada con isotretino\u00edna oral).","journal-title":"Rev Med Chil"},{"issue":"10","key":"1066_CR90","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/j.1365-4362.1986.tb04533.x","volume":"25","author":"E Hoting","year":"1986","unstructured":"Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol. 1986;25(10):660\u20133. https:\/\/doi.org\/10.1111\/j.1365-4362.1986.tb04533.x.","journal-title":"Int J Dermatol"},{"issue":"7","key":"1066_CR91","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/archderm.134.7.884","volume":"134","author":"FG Erdogan","year":"1998","unstructured":"Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol. 1998;134(7):884\u20135. https:\/\/doi.org\/10.1001\/archderm.134.7.884.","journal-title":"Arch Dermatol"},{"issue":"7","key":"1066_CR92","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2165\/00128071-200203070-00005","volume":"3","author":"A Rebora","year":"2002","unstructured":"Rebora A. The management of rosacea. Am J Clin Dermatol. 2002;3(7):489\u201396. https:\/\/doi.org\/10.2165\/00128071-200203070-00005.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1066_CR93","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1177\/120347541201600615","volume":"16","author":"E Rallis","year":"2012","unstructured":"Rallis E, Korfitis C. Isotretinoin for the treatment of granulomatous rosacea: case report and review of the literature. J Cutan Med Surg. 2012;16(6):438\u201341. https:\/\/doi.org\/10.1177\/120347541201600615.","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"1066_CR94","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.jid.2016.01.025","volume":"136","author":"E Sbidian","year":"2016","unstructured":"Sbidian E, Vicaut \u00c9, Chidiack H, et al. A randomized-controlled trial of oral low-dose isotretinoin for difficult-to-treat papulopustular rosacea. J Investig Dermatol. 2016;136(6):1124\u20139. https:\/\/doi.org\/10.1016\/j.jid.2016.01.025.","journal-title":"J Investig Dermatol"},{"issue":"5","key":"1066_CR95","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1365-2230.1984.tb00842.x","volume":"9","author":"JR Marsden","year":"1984","unstructured":"Marsden JR, Shuster S, Neugebauer M. Response of rosacea to isotretinoin. Clin Exp Dermatol. 1984;9(5):484\u20138. https:\/\/doi.org\/10.1111\/j.1365-2230.1984.tb00842.x.","journal-title":"Clin Exp Dermatol"},{"issue":"4 Pt 2 Suppl","key":"1066_CR96","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/s0190-9622(82)70067-2","volume":"6","author":"G Plewig","year":"1982","unstructured":"Plewig G, Nikolowski J, Wolff HH. Action of isotretinoin in acne rosacea and gram-negative folliculitis. J Am Acad Dermatol. 1982;6(4 Pt 2 Suppl):766\u201385. https:\/\/doi.org\/10.1016\/s0190-9622(82)70067-2.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1066_CR97","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jaad.2004.03.033","volume":"51","author":"MT Pelle","year":"2004","unstructured":"Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51(4):499\u2013512. https:\/\/doi.org\/10.1016\/j.jaad.2004.03.033. (quiz 513\u20134).","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1066_CR98","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/der2.100","volume":"2","author":"JW Marson","year":"2021","unstructured":"Marson JW, Baldwin HE. Isotretinoin update. Dermatol Rev. 2021;2(6):331\u201342. https:\/\/doi.org\/10.1002\/der2.100.","journal-title":"Dermatol Rev"},{"issue":"3","key":"1066_CR99","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1524-4725.2009.01080.x","volume":"35","author":"SJ Kempiak","year":"2009","unstructured":"Kempiak SJ, Lee PW, Pelle MT. Rhinophyma treated with cryosurgery. Dermatol Surg. 2009;35(3):543\u20135. https:\/\/doi.org\/10.1111\/j.1524-4725.2009.01080.x.","journal-title":"Dermatol Surg"},{"key":"1066_CR100","doi-asserted-by":"publisher","first-page":"4915416","DOI":"10.1155\/2019\/4915416","volume":"2019","author":"A Abushaala","year":"2019","unstructured":"Abushaala A, Stavrakas M, Khalil H. Microdebrider-assisted rhinophyma excision. Case Rep Otolaryngol. 2019;2019:4915416. https:\/\/doi.org\/10.1155\/2019\/4915416.","journal-title":"Case Rep Otolaryngol."},{"issue":"1","key":"1066_CR101","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/SAP.0b013e31815f12d2","volume":"61","author":"H Sadick","year":"2008","unstructured":"Sadick H, Goepel B, Bersch C, Goessler U, Hoermann K, Riedel F. Rhinophyma: diagnosis and treatment options for a disfiguring tumor of the nose. Ann Plast Surg. 2008;61(1):114\u201320. https:\/\/doi.org\/10.1097\/SAP.0b013e31815f12d2.","journal-title":"Ann Plast Surg"},{"issue":"4","key":"1066_CR102","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/1943387520983117","volume":"14","author":"S Benyo","year":"2021","unstructured":"Benyo S, Saadi RA, Walen S, Lighthall JG. A systematic review of surgical techniques for management of severe rhinophyma. Craniomaxillofac Trauma Reconstr. 2021;14(4):299\u2013307. https:\/\/doi.org\/10.1177\/1943387520983117.","journal-title":"Craniomaxillofac Trauma Reconstr"},{"issue":"1","key":"1066_CR103","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4103\/JCAS.JCAS_139_20","volume":"14","author":"MV Kiehlmann","year":"2021","unstructured":"Kiehlmann MV, Morandi EM, K\u00fchn S, et al. Tangential excision of rhinophyma with the disposable razor blade: simple and cost efficient with aesthetically good results. J Cutan Aesthet Surg. 2021;14(1):72\u20136. https:\/\/doi.org\/10.4103\/JCAS.JCAS_139_20.","journal-title":"J Cutan Aesthet Surg"},{"issue":"7","key":"1066_CR104","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1524-4725.2007.33181.x","volume":"33","author":"M Apikian","year":"2007","unstructured":"Apikian M, Goodman GJ, Roberts S. Management of mild to moderate rhinophyma with a 1,450-nm diode laser: report of five patients. Dermatol Surg. 2007;33(7):847\u201350. https:\/\/doi.org\/10.1111\/j.1524-4725.2007.33181.x.","journal-title":"Dermatol Surg"},{"issue":"4","key":"1066_CR105","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1365-2133.2009.09317.x","volume":"161","author":"V Madan","year":"2009","unstructured":"Madan V, Ferguson JE, August PJ. Carbon dioxide laser treatment of rhinophyma: a review of 124 patients. Br J Dermatol. 2009;161(4):814\u20138. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09317.x.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1066_CR106","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1749-4486.2010.02189.x","volume":"35","author":"J Tahery","year":"2010","unstructured":"Tahery J, Zakaria R, Natt RS. Diode laser treatment of rhinophyma. Clin Otolaryngol. 2010;35(5):442\u20134. https:\/\/doi.org\/10.1111\/j.1749-4486.2010.02189.x.","journal-title":"Clin Otolaryngol"},{"issue":"9 Pt 2","key":"1066_CR107","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1111\/j.1524-4725.2005.31934","volume":"31","author":"GH Fisher","year":"2005","unstructured":"Fisher GH, Geronemus RG. Short-term side effects of fractional photothermolysis. Dermatol Surg. 2005;31(9 Pt 2):1245\u20139. https:\/\/doi.org\/10.1111\/j.1524-4725.2005.31934.","journal-title":"Dermatol Surg"},{"issue":"2","key":"1066_CR108","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/SCS.0b013e31819b9830","volume":"20","author":"F Erisir","year":"2009","unstructured":"Erisir F, Isildak H, Haciyev Y. Management of mild to moderate rhinophyma with a radiofrequency. J Craniofac Surg. 2009;20(2):455\u20136. https:\/\/doi.org\/10.1097\/SCS.0b013e31819b9830.","journal-title":"J Craniofac Surg"},{"issue":"3","key":"1066_CR109","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/00003226-200304000-00009","volume":"22","author":"VC Ghanem","year":"2003","unstructured":"Ghanem VC, Mehra N, Wong S, Mannis MJ. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea. 2003;22(3):230\u20133. https:\/\/doi.org\/10.1097\/00003226-200304000-00009.","journal-title":"Cornea"},{"issue":"2","key":"1066_CR110","first-page":"97","volume":"84","author":"R Odom","year":"2009","unstructured":"Odom R, Dahl M, Dover J, et al. Standard management options for rosacea, part 2: options according to subtype. Cutis. 2009;84(2):97\u2013104.","journal-title":"Cutis"},{"issue":"2","key":"1066_CR111","first-page":"112","volume":"68","author":"EL Tanzi","year":"2001","unstructured":"Tanzi EL, Weinberg JM. The ocular manifestations of rosacea. Cutis. 2001;68(2):112\u20134.","journal-title":"Cutis"},{"issue":"5","key":"1066_CR112","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1468-3083.2009.03132.x","volume":"23","author":"O Bakar","year":"2009","unstructured":"Bakar O, Demircay Z, Toker E, Cakir S. Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin. J Eur Acad Dermatol Venereol. 2009;23(5):544\u20139. https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03132.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1066_CR113","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1080\/09273948.2020.1727531","volume":"29","author":"B Sobolewska","year":"2021","unstructured":"Sobolewska B, Doycheva D, Deuter CM, Schaller M, Zierhut M. Efficacy of topical ivermectin for the treatment of cutaneous and ocular rosacea. Ocul Immunol Inflamm. 2021;29(6):1137\u201341. https:\/\/doi.org\/10.1080\/09273948.2020.1727531.","journal-title":"Ocul Immunol Inflamm"},{"issue":"9","key":"1066_CR114","first-page":"909","volume":"16","author":"LS Gold","year":"2017","unstructured":"Gold LS, Papp K, Lynde C, et al. Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: a randomized, vehicle-controlled study. J Drugs Dermatol. 2017;16(9):909\u201316.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1066_CR115","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjd.19172","volume":"183","author":"AM Kumar","year":"2020","unstructured":"Kumar AM, Chiou AS, Shih YH, Li S, Chang ALS. An exploratory, open-label, investigator-initiated study of interleukin-17 blockade in patients with moderate-to-severe papulopustular rosacea. Br J Dermatol. 2020;183(5):942\u20133. https:\/\/doi.org\/10.1111\/bjd.19172.","journal-title":"Br J Dermatol"},{"key":"1066_CR116","unstructured":"Efficacy and tolerability of erenumab in the management of persistent redness and flushing in rosacea\u2014full text view\u2014ClinicalTrials.gov. 2023."},{"key":"1066_CR117","unstructured":"Therapeutics D. DMT210 topical gel in the treatment of acne rosacea. 11 November, 2024. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03003104. Accessed 15 July 2026."},{"key":"1066_CR118","unstructured":"Maruho Co. L. Study to Evaluate the safety and efficacy of a once-daily CLS001 topical gel versus vehicle. ClinicalTrialsgov. 2023;Identifier NCT02576860. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02576860. Accessed 15 July 2026."},{"key":"1066_CR119","unstructured":"Maruho Co. L. Study to evaluate the long-term safety of a once-daily Omiganan topical gel. ClinicalTrialsgov. 2023;Identifier NCT03590366. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03590366. Accessed 18 July 2026."},{"key":"1066_CR120","unstructured":"LLC A. A study to determine safety and efficacy of B244 in subjects with mild to moderate rosacea. ClinicalTrialsgov. 2023; (Identifier NCT03590366). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03590366. Accessed 21 July 2026."},{"key":"1066_CR121","unstructured":"S.p.A. A. Safety and efficacy of rifaximin in patients with papulopustular rosacea and positive lactulose breath test. Clinicaltrialsgov. 2022;Identifier NCT03864978. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03864978. Accessed 21 July 2026."},{"key":"1066_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106178","volume":"79","author":"J Li","year":"2020","unstructured":"Li J, Yuan X, Tang Y, et al. Hydroxychloroquine is a novel therapeutic approach for rosacea. Int Immunopharmacol. 2020;79:106178. https:\/\/doi.org\/10.1016\/j.intimp.2019.106178.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"1066_CR123","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jaad.2020.05.050","volume":"84","author":"B Wang","year":"2021","unstructured":"Wang B, Yuan X, Huang X, et al. Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: a multicenter, randomized, double-blind, double-dummy, pilot study. J Am Acad Dermatol. 2021;84(2):543\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2020.05.050.","journal-title":"J Am Acad Dermatol"},{"key":"1066_CR124","unstructured":"The Royal College of Ophthalmologists. Clinical guidelines-hydroxychloroquine and chloroquine retinopathy monitoring guideline: recommendations on monitoring. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2020\/12\/Hydroxychloroquine-and-Chloroquine-Retinopathy-Monitoring-Guideline.pdf. Accessed 9 Aug 2022."},{"issue":"7","key":"1066_CR125","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cgh.2008.02.054","volume":"6","author":"A Parodi","year":"2008","unstructured":"Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;6(7):759\u201364. https:\/\/doi.org\/10.1016\/j.cgh.2008.02.054.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"1066_CR126","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jaad.2012.11.038","volume":"68","author":"LB Weinstock","year":"2013","unstructured":"Weinstock LB, Steinhoff M. Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin. J Am Acad Dermatol. 2013;68(5):875\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2012.11.038.","journal-title":"J Am Acad Dermatol"},{"key":"1066_CR127","volume-title":"Integrative dermatology","author":"HE Baldwin","year":"2014","unstructured":"Baldwin HE. Integrative management of rosacea. In: Rupani R, Lio P, editors. Integrative dermatology. Oxford University Press; 2014."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01066-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01066-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01066-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:02:42Z","timestamp":1793638962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01066-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":127,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01066-7","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"5 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DL declares no conflicts of interest. JWM has served as a consultant for Cerave, an advisory board member for La Roche-Posay, Inc. and Ferndale Healthcare, Inc., and has received research grants from the American Academy of Dermatology and La Roche-Posay. HEB serves as an advisor and speaker bureau member to Bausch Health, Mayne, Novan, Galderma, Journey, Sun Pharma, Tarsus, La Roche-Posay and L\u2019Oreal.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Patient consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from patients for the publication of clinical information and accompanying images.","order":4,"name":"Ethics","label":"Patient consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Literature review was performed by JWM and DL. Initial manuscript drafted by JWM and HEB. Revisions performed by JWM and DL. All authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}